Janssen Pharmaceuticals:
In 2008, we entered in an agreement with Janssen Pharmaceuticals (J&J division) under which we provided our proprietary FCCS technology platform to screen for small molecule inhibitors of a set of target proteins

We are currently developing an assay which measures occupancy of a protein of interest in cells, to support a phase 2 clinical trial. Karyopharm is a biotech which discovers and develops drugs directed against nuclear transport targets, for treatment of cancer and other diseases.

We continuously collaborate with SiTools on projects requiring down-regulation of endogenous targets. SiTools produces innovative SiRNA Pools which effectively and specifically down-regulate gene expression

University of Munich (LMU) – Prof. Don Lamb:
We are collaborating with Prof. Don Lamb to establish RICS (Raster imaging correlation spectroscopy) in our lab. With this technique, we will be able to perform correlation spectroscopy directly on targets embedded in membranes of live cells
University of Leipzig – Prof. Annette Beck-Sickinger: 
We collaborate with Prof. Beck-Sickinger, an expert in the GPCR field, to continuously improve and enlarge our GPCR assay offering

Marie-Curie fellowships FP7:
Intana Bioscience hosts postdoc who have been successful in obtaining Marie Curie FP7 fellowships, both from the Sphingonet and the RNAtrain training networks

Max Planck Institute of Biochemistry (MPIB):
We collaborate with Prof. Petra Schwille to continously develop the FCCS technology

Undisclosed partners: 
We have carried out numerous projects for large pharmaceutical companies, which we are not entitled to disclose for confidentiality purposes

We recently published with our customer Merck KGaA the use of FCCS to support the identification of Methionine Aminopeptidase-2 (MetAP-2) inhibitor M8891.

See our new publication on the quantifiaction of target occupancy in tissue:

Check out our new GPCR-ligand interaction assay!